LONDON (Alliance News) - Akers Biosciences Inc Wednesday said it had signed a deal whereby Dubai-based Thirty Six Strategies General Trading LLC will sell Akers' infectious diseases tests exclusively for the next three years in some countries.
In a statement, Akers said the exclusive agreement for its PIFA PLUSS infectious disease rapid assay product line and Tri-Cholesterol "Check" covers Australia, Singapore, Oman and the United Arab Emirates and is subject to performance minimum purchase requirements.
36S will focus on distribution of the rapid HIV, Hepatitis B, Malaria, and Dengue Fever tests as well as the Cholesterol test, to a varied customer base including hospitals, paramedic and emergency services, non-governmental organizations and military forces, Akers said.
Shares of the Nasdaq and AIM-listed company were up 3.6% at 285.00 pence on AIM Wednesday.
By Steve McGrath; stevemcgrath@alliancenews.com; @stevemcgrath1
Copyright 2014 Alliance News Limited. All Rights Reserved.